Skip to main content
. 2014 Mar 13;2014:689852. doi: 10.1155/2014/689852

Table 2.

Observed resistance profiles as a function of the case characteristics (new versus persistent).

Resistance profiles New case N (%) Persistent N (%) P Total N (%)
N T = 1199 N T = 40
Resistant to INH* 84 (7,0) 9 (22,5) 0,002 93 (7,5)
Resistant to RIF* 27 (2,3) 8 (20,0) <0,001 35 (2,8)
Resistant to EMB* 6 (0,5) 0 1,000 6 (0,5)
Resistant to SM* 66 (5,5) 1 (2,5) 0,720 67 (5,4)
Resistant to PZA* 13 (1,1) 0 1,000 13 (1,1)

Monoresistant to INH** 50 (4,2) 2 (5,0) 0,683 52 (4,2)
Monoresistant to RIF** 7 (0,6) 1 (2,5) 0,231 8 (0,7)
Monoresistant to EMB** 0 0 0
Monoresistant to SM** 40 (3,3) 1 (2,5) 1,000 41 (3,3)
Monoresistant to PZA** 4 (0,3) 0 1,000 4 (0,3)

Resistant to 1 AB*** 101 (8,4) 4 (10) 0,770 105 (8,5)
Resistant to 2 AB*** 32 (2,7) 7 (17,5) <0,001 39 (3,1)
Resistant to 3 AB*** 5 (0,4) 0 1,000 5 (0,4)
Resistant to 4 AB*** 4 (0,3) 0 1,000 4 (0,3)

*comprises all isolates resistant to the respective drugs (irrespective of other associated resistances).

**Isolates resistant to only INH (isoniazid), RIF (rifampicin), EMB (ethambutol), SM (streptomycin), or PZA (pyrazinamide), respectively.

***Strains resistant to 1, 2, 3, or 4 of the tested antibiotics (AB), no strain displayed resistance to all drugs.